Endocrine Abstracts

Introduction: Severe hyponatraemia is a medical emergency and can be life-threatening. It requires prompt assessment, investigation and treatment which can be a challenge as it presents to multiple departments. We therefore looked to undertake a review of severe hyponatraemia cases in our 1000-bedded acute trust with the aim of determining most appropriate care.Aims and methods: Retrospective notes review of all patients with Na ≤110 mmol/l between...

Patients with diabetes represent 15-20% of the total adult population in UK hospitals. Insulin is now recognised as the drug with the highest number of prescribing errors in the NHS. In order to determine insulin-related glycaemic morbidity we reviewed a random representative sample of 50 insulin prescription and administration records (25 medical and 25 surgical)over a 4 week period (11 T1DM, 39 T2DM) Initially we audited the legality of the prescriptions against well-describ...

Grave’s disease is an auto-immune condition associated with hyperthyroidism caused by TSH-receptor antibodies (TRAB) expressed by follicular cells of the thyroid gland. Grave’s ophthalmopathy has been reported in 25% of the patients and is rarely associated with dermopathy and thyroid acropachy. Management is by anti-thyroid drugs, radioactive iodine ablation or surgery, either alone or in combination. We present a rare case of resistant Graves who has detectable ant...

Background: We previously published data for short-term outcomes in patients with SIADH-related hyponatraemia unresponsive to fluid restriction and treated with tolvaptan. In light of concerns over longer-term side-effects we have revisited the topic and extended both group size and follow-up period to determine longer-term safety and treatment implications.Aims/methods: We report ongoing treatment outcomes (case-note review) for 25 patients (age 71&#177...

Prior to May 2011, we ran four separate consultant-led endocrine services with six-eight new patient referrals identifiable per week with hyperthyroidism. These were seen ‘ad hoc’ in general endocrine clinics, where their needs were not prioritised compared to other endocrine referrals, resulting in concern around the timeliness of their care.We identified 203 patients under active follow-up (FU) (active=on anti-thyroid medications or within 6 ...